Trial Profile

Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibuprofen+sodium cromoglicate (Primary) ; Ibuprofen; Sodium cromoglicate
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use
Acronyms COGNITE
Sponsors AZTherapies

Most Recent Events

20 Nov 2020 Status changed from active, no longer recruiting to completed.
18 Nov 2020 According to an AZTherapies media release, the company has completed the last patient/last visit in this study. Top-line data from this study is expected in the first quarter of 2021.
22 Jul 2020 According to an AZTherapies media release, the company expects to complete this study in late 2020 and data unblinding in the first quarter of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com